(Z)-Leukadherin-1 ADH-503 free base|cas:2055362-72-4|西域试剂

(Z)-Leukadherin-1 ADH-503 free base,98.0%

产品编号：Bellancom-15701A| CAS NO：2055362-72-4| 分子式：C₂₂H₁₅NO₄S₂| 分子量：421.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15701A	￥550.00	杭州北京（现货）
Bellancom-15701A	￥900.00	杭州北京（现货）
Bellancom-15701A	￥2500.00	杭州北京（现货）
Bellancom-15701A	￥3500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

(Z)-Leukadherin-1 ADH-503 free base

产品介绍

(Z)-Leukadherin-1 (ADH-503 free base) 是一种具有口服活性的，变构的 CD11b 激动剂。(Z)-Leukadherin-1 可以导致与肿瘤相关的巨噬细胞重新极化，减少肿瘤浸润性免疫抑制骨髓细胞的数量，并增强树突状细胞的反应。

生物活性

(Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses.

体外研究

(Z)-Leukadherin-1 (ADH-503 free base; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b⁺ cells and subsets of CD11b⁺ monocytes, granulocytes, eosinophils, and macrophages.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

(Z)-Leukadherin-1 (ADH-503 free base; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
(Z)-Leukadherin-1 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras^G12D/p53^flox/flox]
Dosage:	30, 60, or 120 mg/kg
Administration:	Oral gavage; 60 days
Result:	Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.

Animal Model:	Male rats
Dosage:	30, 100 mg/kg (Pharmacokinetic Analysis)
Administration:	Oral gavage twice a day; on days 1 and 5
Result:	Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras^G12D/p53^flox/flox]
Dosage:	30, 60, or 120 mg/kg
Administration:	Oral gavage; 60 days
Result:	Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.

Animal Model:	Male rats
Dosage:	30, 100 mg/kg (Pharmacokinetic Analysis)
Administration:	Oral gavage twice a day; on days 1 and 5
Result:	Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.

性状

Solid

溶解性数据

In Vitro:

DMSO : 4.55 mg/mL (10.80 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3725 mL	11.8627 mL	23.7254 mL
5 mM	0.4745 mL	2.3725 mL	4.7451 mL
10 mM	0.2373 mL	1.1863 mL	2.3725 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式